Nguyen Nam P, Mohammadianpanah Mohammad, SunMyint Arthur, Page Brandi R, Vinh-Hung Vincent, Gorobets Olena, Arenas Meritxell, Mazibuko Thandeka, Giap Huan, Vasileiou Maria, Dutheil Fabien, Tuscano Carmelo, Karlsson Ulf Lennart, Dahbi Zineb, Natoli Elena, Li Eric, Kim Lyndon, Oboite Joan, Oboite Eromosele, Bose Satya, Vuong Te
Department of Radiation Oncology, Howard University, Washington, DC, United States.
Colorectal Research Center, Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Front Oncol. 2024 Feb 22;14:1325610. doi: 10.3389/fonc.2024.1325610. eCollection 2024.
The standard of care for locally advanced rectal cancer is total neoadjuvant therapy followed by surgical resection. Current evidence suggests that selected patients may be able to delay or avoid surgery without affecting survival rates if they achieve a complete clinical response (CCR). However, for older cancer patients who are too frail for surgery or decline the surgical procedure, local recurrence may lead to a deterioration of patient quality of life. Thus, for clinicians, a treatment algorithm which is well tolerated and may improve CCR in older and frail patients with rectal cancer may improve the potential for prolonged remission and potential cure. Recently, immunotherapy with check point inhibitors (CPI) is a promising treatment in selected patients with high expression of program death ligands receptor 1 (PD- L1). Radiotherapy may enhance PD-L1 expression in rectal cancer and may improve response rate to immunotherapy. We propose an algorithm combining immunotherapy and radiotherapy for older patients with locally advanced rectal cancer who are too frail for surgery or who decline surgery.
局部晚期直肠癌的标准治疗方案是新辅助全疗程治疗后进行手术切除。目前的证据表明,如果部分患者实现了完全临床缓解(CCR),他们可能能够推迟或避免手术,且不影响生存率。然而,对于因身体过于虚弱而无法进行手术或拒绝手术的老年癌症患者,局部复发可能会导致患者生活质量下降。因此,对于临床医生而言,一种耐受性良好且可能提高老年体弱直肠癌患者CCR的治疗方案,或许能够提高延长缓解期和实现潜在治愈的可能性。近来,使用检查点抑制剂(CPI)的免疫疗法对于程序性死亡配体受体1(PD-L1)高表达的特定患者是一种很有前景的治疗方法。放疗可能会增强直肠癌中PD-L1的表达,并可能提高免疫治疗的反应率。我们提出一种针对因身体过于虚弱而无法进行手术或拒绝手术的老年局部晚期直肠癌患者的免疫疗法与放疗相结合的治疗方案。